By Chemical Treatment Patents (Class 435/238)
-
Publication number: 20100279968Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.Type: ApplicationFiled: December 27, 2006Publication date: November 4, 2010Applicant: Koronis Pharmaceuticals, Inc.Inventors: Ling Li, Alexander Gall, Richard Daifuku
-
Publication number: 20100260798Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: SANOFI PASTEURInventors: Virginie Fabre, Céline Rocca, Pierre Riffard, Eric Calvosa
-
Publication number: 20100260710Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: ApplicationFiled: April 7, 2010Publication date: October 14, 2010Applicant: Idenix Pharmaceuticals, Inc.Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Michel Derock, Frederic Leroy, Jean-Christophe Meillon, Thierry Convard, Dominique Surleraux
-
Publication number: 20100249181Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: ApplicationFiled: June 10, 2010Publication date: September 30, 2010Applicant: ABBOTT LABORATORIESInventors: David A. DeGoey, Charles A. Flentge, William J. Flosi, David J. Grampovnik, Dale J. Kempf, Larry L. Klein, Ming C. Yeung, John T. Randolph, Xiu C. Wang, Su Yu
-
Publication number: 20100234434Abstract: Disclosed herein are compounds, compositions and methods for treating or ameliorating flavivirus infections. This is particularly important because the present disclosure provides methods for treating flavivirus infections for which there is no effective vaccine.Type: ApplicationFiled: March 15, 2007Publication date: September 16, 2010Inventor: Eric Barklis
-
Publication number: 20100221215Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: February 9, 2010Publication date: September 2, 2010Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Patent number: 7776322Abstract: This invention relates to viral vector particles, including capsid proteins with an attachment site for the specific chemical modification of the vector particles. Furthermore, the invention relates to procedures for the production of these viral vector particles. Furthermore, the invention relates to the use of these viral vector particles as a therapeutic, prophylactic or diagnostic means in humans and primates as well as other vertebrates like cattle, pigs, birds, fish, or rodents.Type: GrantFiled: May 2, 2005Date of Patent: August 17, 2010Inventors: Stefan Kochanek, Florian Kreppel
-
Patent number: 7767210Abstract: The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue fever virus, Hepatitis C virus, Pestiviruses, Bovine viral diarrhea virus, and Classical Swine fever virus, wherein the vaccine comprises the RNA virus or immunogenic portions thereof, which have been treated with and rendered non-pathogenic by a phenothiazine dye and visible light. The invention includes novel strains of WNV for use in producing a vaccine.Type: GrantFiled: December 14, 2006Date of Patent: August 3, 2010Assignee: The Board of Regents of the University of OklahomaInventors: Dirk P. Dittmer, Robert A. Floyd
-
Publication number: 20100137437Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.Type: ApplicationFiled: May 18, 2007Publication date: June 3, 2010Applicant: VIROBLOCK S.A.Inventors: Thierry Pelet, Donald F.H. Wallach, Francesca Wallach
-
Patent number: 7727757Abstract: Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.Type: GrantFiled: September 22, 2003Date of Patent: June 1, 2010Inventor: Adan Rios
-
Publication number: 20100129893Abstract: The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.Type: ApplicationFiled: January 25, 2010Publication date: May 27, 2010Inventors: Robert W. Van Holten, Stephen M. Autenrieth
-
Publication number: 20100119558Abstract: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.Type: ApplicationFiled: November 10, 2009Publication date: May 13, 2010Applicants: SCANDIVIR AB, LIFE SCIENCE NUTRITION ASInventors: Jan Remmereit, Dan Edwall, Anders Struksnes
-
Publication number: 20100105110Abstract: This invention provides methods for adenoviral vector synthesis. The present invention further provides methods for binding adenovirus terminal protein obtained from virus to linear DNA. The present invention further provides a recombinant adenovirus from which the adenovirus terminal protein can be purified with an inverted terminal repeat DNA sequence.Type: ApplicationFiled: October 28, 2008Publication date: April 29, 2010Inventor: Xavier Danthinne
-
Publication number: 20100074889Abstract: The present invention discloses compounds of formula (I), or its ?-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: September 11, 2009Publication date: March 25, 2010Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Publication number: 20100047897Abstract: A process for producing a targeted gene and/or drug delivery system for liver cells comprising the steps of: i. chemical reduction of Sendai virus for reduction of HN protein; ii. subjecting the reduced virus to the step of dialysis for removal of the reducing agent; iii. solubilizing the reduced virus with a detergent to obtain a solution; iv. centrifuging the solution to separate the insolubles consisting of reduced HN protein and core of said virus; v. adding histidylated lipid to the supernatant; vi. adding the drug or gene after addition of the lipid; vii. removing the detergent from the envelope and then subjecting it to the step of centrifugation to obtain His lipid F-virosomes with entrapped drug or DNA.Type: ApplicationFiled: February 24, 2006Publication date: February 25, 2010Inventors: Santosh K Verma, Nishi Raj Sharma, Valluripalli Vinod Kumar, Arabinda Chaudhuri, Debi P. Sarkar, Prashant Mani, Anuja Krishnan, Bathula Surendar Reddy, Rajandra P. Roy
-
Publication number: 20100021989Abstract: The formulations have an antimicrobial, antiviral, and anti-pathogenic composition that combines, in various forms, a redox-active polyphenol, an oxidizing agent, and/or a redox-active, transition metal ion and/or electrochemical potential. The composition relates to methods for decreasing or eliminating the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for treating herpes simplex and HIV viruses and drug-resistant bacteria, and for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods, compositions, electrochemical devices, and storage containers for decreasing the infectivity of pathogenic organisms in pharmaceuticals, medical devices, personal care products, recreational products, and foodstuffs.Type: ApplicationFiled: July 28, 2009Publication date: January 28, 2010Inventors: Steve Baugh, Thomas Hnat, Alok Nigam
-
Publication number: 20100003214Abstract: The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: November 14, 2008Publication date: January 7, 2010Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
-
Publication number: 20090326043Abstract: Disclosed is an anti-viral therapeutic that inactivates the Human Immunodeficiency Virus (HIV) RNA by siDNA. The siDNA antiviral therapeutic is effective in the treatment and inactivation of cell free virus particles before infection and/or in the treatment and prevention of HIV infections inside the cell. The invention exploits the HIV RNase H activity of the reverse transcriptase which is essential for viral replication, causing premature cleavage and degradation of the viral RNA genome.Type: ApplicationFiled: June 12, 2009Publication date: December 31, 2009Inventor: Karin Moelling
-
Publication number: 20090326019Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.Type: ApplicationFiled: June 11, 2009Publication date: December 31, 2009Inventors: Yat Sun Or, Jiang Long, Ce Wang, Lu Ying, Yao-Ling Qiu
-
Publication number: 20090317418Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.Type: ApplicationFiled: February 22, 2006Publication date: December 24, 2009Applicant: THE GOV'T OF USOA as represented by the SECRETARY OF THE DEPT OF HHSInventors: Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
-
Publication number: 20090304799Abstract: The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.Type: ApplicationFiled: April 21, 2009Publication date: December 10, 2009Inventors: James R. Baker, JR., Tarek Hamouda, Joyce A. Sutcliffe
-
Publication number: 20090291428Abstract: The invention encompasses an antibody that binds to and substantially inhibits the activity of at least one poxvirus complement inhibitor. Additionally, the application encompasses methods of detecting a poxvirus complement inhibitor and methods of decreasing the activity of a poxvirus complement inhibitor.Type: ApplicationFiled: May 20, 2009Publication date: November 26, 2009Applicant: The Washington UniversityInventors: John P. Atkinson, M. Kathryn Liszewski, Marilyn K. Leung, Paula Bertram
-
Publication number: 20090285815Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.Type: ApplicationFiled: March 21, 2008Publication date: November 19, 2009Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
-
Publication number: 20090281041Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.Type: ApplicationFiled: May 5, 2009Publication date: November 12, 2009Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
-
Publication number: 20090280473Abstract: Methods of inhibiting viral infection of a eukaryotic cell by a target virus having a class II virus fusion protein are provided. Also provided are methods of screening a test compound for the ability to inhibit infection by a virus having a class II viral fusion protein. Additionally provided herewith are aqueous-soluble proteins comprising a portion of a class II viral fusion protein comprising a Domain III of the viral fusion protein.Type: ApplicationFiled: May 4, 2006Publication date: November 12, 2009Inventors: Margaret Kielian, Maofu Liao
-
Patent number: 7611831Abstract: Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 100 ?m to about 1500 ?m. The device can be used to adsorb and remove a pathogen-inactivating compounds from a biological composition such as a blood product.Type: GrantFiled: October 4, 2005Date of Patent: November 3, 2009Assignee: Cerus CorporationInventor: Derek J. Hei
-
Publication number: 20090246216Abstract: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5? non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.Type: ApplicationFiled: March 16, 2009Publication date: October 1, 2009Applicant: The Research Foundation of State University of New YorkInventors: Eckard Wimmer, Jeronimo Cello, Aniko Paul, Hidemi Toyoda, Jiang Yin
-
Publication number: 20090247612Abstract: The present invention concerns the inactivation of viral infectivity in a cell-free environment as well as the preparation of a pharmaceutical agent and a method therefore. According to the invention the use of a sequence of oligodeoxynucleotides or oligoribonucleotides or a chimera or a combination thereof capable of binding to conserved regions of viral RNA for the inactivation of viral infectivity outside in a cell-free environment is intended. Furthermore said sequences are used for the preparation of a pharmaceutical agent for the inactivation of viral infectivity.Type: ApplicationFiled: October 27, 2006Publication date: October 1, 2009Inventor: Karin Möelling
-
Publication number: 20090247473Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.Type: ApplicationFiled: March 30, 2009Publication date: October 1, 2009Applicant: THE GOVERNMENT OF THE U.S.A.,as represented by the Secretary of the Dept. of Health & Human ServicesInventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
-
Publication number: 20090247639Abstract: The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 26, 2009Publication date: October 1, 2009Inventor: Albert T. Profy
-
Publication number: 20090238794Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: March 19, 2009Publication date: September 24, 2009Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
-
Publication number: 20090233972Abstract: The present invention discloses compounds of Formulae (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing viruses, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.Type: ApplicationFiled: March 12, 2009Publication date: September 17, 2009Inventors: YAT SUN OR, LU YING, CE WANG, JIANG LONG, YAO-LING QIU
-
Publication number: 20090226488Abstract: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ems in addition to the inactivation of the (hypothesized) immunomodulating activity residing in Npro. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.Type: ApplicationFiled: May 11, 2009Publication date: September 10, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Gregor MEYERS, Andreas EGE, Christiane MEYER, Martina von FREYBURG
-
Publication number: 20090221602Abstract: The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.Type: ApplicationFiled: May 6, 2009Publication date: September 3, 2009Applicant: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Francesca Mazzei, David Kay, Andrew Miller
-
Publication number: 20090209583Abstract: The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.Type: ApplicationFiled: June 22, 2007Publication date: August 20, 2009Inventors: Herman De Kock, Tim Hugo Maria Jonckers, Paul Jozef Gabriel Maria Boonants, Stefaan Julien Last, Inge Dierynck, Judith Eva Baumeister, Gerben Albert Van ' T Klooster
-
Publication number: 20090181931Abstract: The present invention relates to pyrimidine compounds and their use as pharmacologically active agents capable of suppressing and inhibiting viruses (e.g., oncolytic viruses). The subject compounds and compositions are particularly useful in treating and suppressing human oncolytic adenovirus infection.Type: ApplicationFiled: January 16, 2008Publication date: July 16, 2009Applicant: ONCOLYS BIOPHARMA, INC.Inventors: Yasuo Urata, Masaaki Ouchi, Toshiyoshi Fujiwara
-
Publication number: 20090176784Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: ApplicationFiled: September 17, 2008Publication date: July 9, 2009Applicant: ABBOTT LABORATORIESInventors: Pamela L. Donner, John T. Randolph, Allan C. Krueger, David A. Betebenner, Douglas K. Hutchinson, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, John K. Pratt, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, John E. Hengeveld, Rodger F. Henry, Xiaochun Lou, Geoff G.Z. Zhang
-
Patent number: 7556814Abstract: An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.Type: GrantFiled: October 22, 2004Date of Patent: July 7, 2009Inventor: Nelson M. Karp
-
Publication number: 20090170846Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus “HIV” integrase enzyme. Formula (I).Type: ApplicationFiled: September 22, 2006Publication date: July 2, 2009Inventors: Klaus Ruprecht Dress, Michael Bruno Plewe, Ted William Johnson, Steven Paul Tanis, Khanh Tuan Tran
-
Publication number: 20090155349Abstract: Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR1 and —OR2 each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R3, R4, R5, R6, R10, R11, R12 and R13 each independently represents a hydrogen, or a lower alkyl; and R7, R8 and R9 each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R7, R8 and R9 represents a hydrogen, then —OR1, —OR2 and the othType: ApplicationFiled: February 23, 2007Publication date: June 18, 2009Inventors: Jonathan Daniel Heller, Scott Matthew Laster, Rocio Alejandra Lopez, Neil Frazer
-
Publication number: 20090105279Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: April 23, 2009Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu, Zheng-Yu Yang
-
Publication number: 20090105151Abstract: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.Type: ApplicationFiled: July 14, 2008Publication date: April 23, 2009Inventors: Jeffrey Glenn, Nam-Joon Cho, Curtis W. Frank, Kwang Ho Cheong
-
Patent number: 7521219Abstract: The present invention is directed to a method for producing commercial quantities of baculovirus using a combination of methods involving producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture. A two step method was developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.Type: GrantFiled: November 10, 2004Date of Patent: April 21, 2009Assignee: The University of QueenslandInventors: Steven Reid, Linda Lua
-
Publication number: 20090099096Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 19, 2007Publication date: April 16, 2009Inventors: Carina E. Cannizzaro, James M. Chen, Manoj C. Desai, Michael L. Mitchell, Sundaramoorthi Swaminathan, Lianhong Xu
-
Publication number: 20090099239Abstract: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.Type: ApplicationFiled: June 23, 2006Publication date: April 16, 2009Inventors: Gary Dinneen Ewart, Wayne Morris Best
-
Publication number: 20090098161Abstract: A method of making an immunogenic composition using inactivated HIV Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoraten and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.Type: ApplicationFiled: December 5, 2008Publication date: April 16, 2009Inventor: Nelson M. Karp
-
Publication number: 20090060866Abstract: Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I?, II?, I?, II?, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: Idenix Pharmaceuticals, Inc.Inventors: Cyril Dousson, Dominique Surleraux, Arlene Roland, Claire Pierra, Daniel Da Costa
-
Publication number: 20090053294Abstract: Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.Type: ApplicationFiled: October 31, 2006Publication date: February 26, 2009Inventor: Patrick T. Prendergast
-
Publication number: 20090054451Abstract: The present invention is directed to novel piperidine derivatives and to the use of piperidine derivatives of formula I as agonists of chemokine receptor activity.Type: ApplicationFiled: August 4, 2008Publication date: February 26, 2009Applicant: Euroscreen S.A.Inventors: Jacques Huck, Frederic Ooms, Christian Tyrchan, Hamid R. Hoveyda
-
Patent number: 7494799Abstract: The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory optimization of the paramunizing activities for use in the prophylaxis and therapy of various human and animal dysfunctions.Type: GrantFiled: January 21, 2005Date of Patent: February 24, 2009Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr